$CTMX News

JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway

Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...

CytomX Therapeutics (NASDAQ:CTMX) Shares Plunge After Q2 Revenue and EPS Miss Estimates

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

CytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why

How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments

CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CytomX (CTMX) Q4 2025 Earnings Transcript

How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data And Risks

CytomX Therapeutics: Cashed Up With Catalysts Ahead

CytomX Therapeutics to Present at Upcoming June Investor Conferences

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

New Forecasts: Here's What Analysts Think The Future Holds For CytomX Therapeutics, Inc. (NASDAQ:CTMX)